Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Complix NV
This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.
The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.
J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.
Complix NV aims to construct therapeutic proteins that can bind to molecular targets no antibody has ever been able to reach, and that small molecules cannot fully inhibit. Its Alphabodies are structurally distinct from antibodies and from most other scaffolds – they can be designed to penetrate cell membranes, to remain stable inside cells, and to bind intracellular targets.